Ultragenyx Pharmaceutical Inc.
For the period ended Dec 31, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity (Deficit)
| (In millions) · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · Treasury · Deferred Compensation · TotalStockholders' | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Capital · Income (Loss) · Deficit · Stock · Obligation · Equity (Deficit) | ||||||||||
| Balance as of December 31, 2022 | 70.2 | $3,140 | $(7) | $(2,781) | $— | $— | $352 | |||
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering, net of issuance costs | 9.8 | 326 | — | — | — | — | 326 | |||
| Issuance of common stock in connection with at-the-market offering, net of issuance costs | 1.2 | 53 | — | — | — | — | 53 | |||
| Stock-based compensation | — | 135 | — | — | — | — | 135 | |||
| Issuance of common stock under equity plan awards, net of tax | 1.1 | 8 | — | — | — | — | 8 | |||
| Other comprehensive income | — | — | 8 | — | — | — | 8 | |||
| Net loss | — | — | — | (607) | — | — | (607) | |||
| Balance as of December 31, 2023 | 82.3 | $3,662 | $1 | $(3,388) | $— | $— | $275 | |||
| Issuance of common stock and pre-funded warrants in connection with underwritten public offering, net of issuance costs | 8.8 | 381 | — | — | — | — | 381 | |||
| Stock-based compensation | — | 159 | — | — | — | — | 159 | |||
| Issuance of common stock under equity plan awards, net of tax | 1.4 | 11 | — | — | — | — | 11 | |||
| Deferred compensation | — | — | — | — | (4) | 4 | — | |||
| Other comprehensive loss | — | — | (2) | — | — | — | (2) | |||
| Net loss | — | — | — | (569) | — | — | (569) | |||
| Balance as of December 31, 2024 | 92.5 | $4,213 | $(1) | $(3,957) | $(4) | $4 | $255 | |||
| Issuance of common stock in connection with at-the-market offering, net | 2.2 | 80 | — | — | — | — | 80 | |||
| Stock-based compensation | — | 152 | — | — | — | — | 152 | |||
| Issuance of common stock under equity plan awards, net of tax | 1.9 | 6 | — | — | — | — | 6 | |||
| Deferred compensation | — | — | — | — | (4) | 4 | — | |||
| Other comprehensive income | — | — | 2 | — | — | 2 | ||||
| Net loss | — | — | — | (575) | — | — | (575) | |||
| Balance as of December 31, 2025 | 96.6 | $4,451 | $1 | $(4,532) | $(8) | $8 | $(80) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.